These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

645 related items for PubMed ID: 9920056

  • 21. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly.
    de Herder WW, Taal HR, Uitterlinden P, Feelders RA, Janssen JA, van der Lely AJ.
    Eur J Endocrinol; 2005 Jul; 153(1):67-71. PubMed ID: 15994747
    [Abstract] [Full Text] [Related]

  • 22. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study.
    Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R.
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3746-56. PubMed ID: 19622615
    [Abstract] [Full Text] [Related]

  • 23. Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide.
    Jallad RS, Bronstein MD.
    Neuroendocrinology; 2009 Oct; 90(1):82-92. PubMed ID: 19439914
    [Abstract] [Full Text] [Related]

  • 24. [Lowered ghrelin levels in acromegaly—normalization after treatment].
    Kozakowski J, Rabijewski M, Zgliczyński W.
    Endokrynol Pol; 2005 Oct; 56(6):862-70. PubMed ID: 16821203
    [Abstract] [Full Text] [Related]

  • 25. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center.
    Barrande G, Pittino-Lungo M, Coste J, Ponvert D, Bertagna X, Luton JP, Bertherat J.
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3779-85. PubMed ID: 11061538
    [Abstract] [Full Text] [Related]

  • 26. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy.
    Colao A, Baldelli R, Marzullo P, Ferretti E, Ferone D, Gargiulo P, Petretta M, Tamburrano G, Lombardi G, Liuzzi A.
    J Clin Endocrinol Metab; 2000 Jan; 85(1):193-9. PubMed ID: 10634386
    [Abstract] [Full Text] [Related]

  • 27. Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency.
    Colao A, di Somma C, Cuocolo A, Spinelli L, Tedesco N, Pivonello R, Bonaduce D, Salvatore M, Lombardi G.
    J Clin Endocrinol Metab; 2001 May; 86(5):1874-81. PubMed ID: 11344175
    [Abstract] [Full Text] [Related]

  • 28. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly.
    Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F.
    Growth Horm IGF Res; 2005 Jun; 15(3):200-6. PubMed ID: 15935982
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Does the age of onset of growth hormone deficiency affect cardiac performance? A radionuclide angiography study.
    Colao A, Cuocolo A, Di Somma C, Cerbone G, Morte AM, Pivonello R, Nicolai E, Salvatore M, Lombardi G.
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):447-55. PubMed ID: 10762287
    [Abstract] [Full Text] [Related]

  • 31. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
    Damjanovic SS, Neskovic AN, Petakov MS, Popovic V, Macut D, Vukojevic P, Joksimovic MM.
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
    Freda PU, Post KD, Powell JS, Wardlaw SL.
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3808-16. PubMed ID: 9814451
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Serum ghrelin levels in acromegaly: effects of surgical and long-acting octreotide therapy.
    Freda PU, Reyes CM, Conwell IM, Sundeen RE, Wardlaw SL.
    J Clin Endocrinol Metab; 2003 May; 88(5):2037-44. PubMed ID: 12727951
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ, Plöckinger U.
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [Abstract] [Full Text] [Related]

  • 38. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly.
    Biermasz NR, van Dulken H, Roelfsema F.
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4596-602. PubMed ID: 11134114
    [Abstract] [Full Text] [Related]

  • 39. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly.
    Espinosa-de-los-Monteros AL, Mercado M, Sosa E, Lizama O, Guinto G, Lopez-Felix B, Garcia O, Hernández I, Ovalle A, Mendoza V.
    J Neurosurg; 2002 Aug; 97(2):287-92. PubMed ID: 12186455
    [Abstract] [Full Text] [Related]

  • 40. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?
    Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM.
    J Clin Endocrinol Metab; 2003 Jul; 88(7):3090-8. PubMed ID: 12843148
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.